Mainstay Medical – Interim Management Statement
on 09/11/2015 11:45
mainstay
Mainstay Medical Applies for CE Mark for ReActiv8®
on 02/11/2015 11:38
A key step towards European commercialisation of innovative treatment of chronic low back pain
Read more
Read more
Positive Results for Mainstay Medical’s Clinical Trial of ReActiv8®
on 31/08/2015 11:34
Clinically important, statistically significant, and lasting improvement in pain, disability, and quality of life for people with Chronic Low Back Pain and limited treatment options.
Read more
Read more
